Wednesday, August 25, 2021

Bharat Biotech#39;s Chikungunya vaccine: Phase 2/3 trial begins

Bharat Biotech#39;s Chikungunya vaccine: Phase 2/3 trial begins The Global Chikungunya Vaccine Clinical Development Program (GCCDP) seeks to develop and manufacture an affordable Chikungunya vaccine with the aim of achieving WHO prequalification to enable its distribution in low- and middle-income countries.

from Moneycontrol Business News https://ift.tt/2WrF8ZE
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Bajaj Auto shares fall 2% as firm, subsidiary fall prey to ransomware attack

Bajaj Auto shares dipped 2% following a ransomware attack on its systems and subsidiary, Bajaj Auto Technology Ltd, on June 23, 2026. The co...